Bailard’s Sutro Biopharma STRO Stock Holding History

Bailard’s Portfolio STRO Stock Details STRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-2,030	Closed	-$164K	–	786
2022 Q4	$164K	Buy	+2,030	New	+$141K	0.01%	668
2021 Q4	–	Sell	-1,130	Closed	-$213K	–	780
2021 Q3	$213K	Buy	+1,130	New	+$215K	0.01%	660

Other funds holding STRO

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Bailard's STRO Position: Q1 2023 in Review

Bailard sold out of Sutro Biopharma (STRO) in Q1 2023, closing a stake of 2,030 shares — an estimated $164K sold.

Bailard first reported a position in STRO in Q3 2021 and held it in 2 quarters. The position peaked at $213K in Q3 2021. 115 funds tracked by Wall St. Rank hold STRO as of Q1 2023.

Bailard reported no remaining Sutro Biopharma position as of Q1 2023 after selling out during the quarter.
Bailard sold 2,030 Sutro Biopharma shares in Q1 2023, an estimated $164K.
Bailard first reported a position in Sutro Biopharma in Q3 2021 and held it in 2 quarters.
Bailard's Sutro Biopharma position peaked at $213K in Q3 2021.
115 funds tracked by Wall St. Rank held Sutro Biopharma as of Q1 2023.

Based on Bailard's 13F filing for Q1 2023, filed 8 May 2023.